KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Gross Margin (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Gross Margin data on record, last reported at 136.63% in Q4 2025.

  • For Q4 2025, Gross Margin rose 12735.0% year-over-year to 136.63%; the TTM value through Dec 2025 reached 87.12%, up 1817.0%, while the annual FY2025 figure was 87.12%, 1817.0% up from the prior year.
  • Gross Margin reached 136.63% in Q4 2025 per AQST's latest filing, up from 64.82% in the prior quarter.
  • Across five years, Gross Margin topped out at 231.82% in Q4 2022 and bottomed at 123.3% in Q2 2021.
  • Average Gross Margin over 5 years is 69.37%, with a median of 65.6% recorded in 2021.
  • Peak YoY movement for Gross Margin: skyrocketed 48450bps in 2021, then crashed -17333bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 69.62% in 2021, then skyrocketed by 233bps to 231.82% in 2022, then plummeted by -75bps to 58.49% in 2023, then tumbled by -84bps to 9.28% in 2024, then skyrocketed by 1373bps to 136.63% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 136.63% in Q4 2025, 64.82% in Q3 2025, and 54.4% in Q2 2025.